160 related articles for article (PubMed ID: 14612547)
1. Fractalkine mediates natural killer-dependent antitumor responses in vivo.
Lavergne E; Combadière B; Bonduelle O; Iga M; Gao JL; Maho M; Boissonnas A; Murphy PM; Debré P; Combadière C
Cancer Res; 2003 Nov; 63(21):7468-74. PubMed ID: 14612547
[TBL] [Abstract][Full Text] [Related]
2. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells.
Xin H; Kikuchi T; Andarini S; Ohkouchi S; Suzuki T; Nukiwa T; Huqun ; Hagiwara K; Honjo T; Saijo Y
Eur J Immunol; 2005 May; 35(5):1371-80. PubMed ID: 15789339
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
4. Single CX3CL1-Ig DNA administration enhances T cell priming in vivo.
Iga M; Boissonnas A; Mahé B; Bonduelle O; Combadière C; Combadière B
Vaccine; 2007 Jun; 25(23):4554-63. PubMed ID: 17493713
[TBL] [Abstract][Full Text] [Related]
5. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
6. Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells.
Zhang X; Wei H; Wang H; Tian Z
Oncol Rep; 2006 Feb; 15(2):485-8. PubMed ID: 16391873
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector.
Gao JQ; Tsuda Y; Katayama K; Nakayama T; Hatanaka Y; Tani Y; Mizuguchi H; Hayakawa T; Yoshie O; Tsutsumi Y; Mayumi T; Nakagawa S
Cancer Res; 2003 Aug; 63(15):4420-5. PubMed ID: 12907614
[TBL] [Abstract][Full Text] [Related]
8. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system.
Morita Y; Matsuda M; Hanamoto H; Shimada T; Tatsumi Y; Maeda Y; Kanamaru A
Clin Immunol; 2004 Oct; 113(1):109-16. PubMed ID: 15380536
[TBL] [Abstract][Full Text] [Related]
9. Activation of human natural killer cells by recombinant membrane-expressed fractalkine on the surface of tumor cells.
Zhang X; Wei H; Chen Q; Tian Z
Oncol Rep; 2007 Jun; 17(6):1371-5. PubMed ID: 17487393
[TBL] [Abstract][Full Text] [Related]
10. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1.
Guo J; Chen T; Wang B; Zhang M; An H; Guo Z; Yu Y; Qin Z; Cao X
Immunol Lett; 2003 Oct; 89(1):1-7. PubMed ID: 12946858
[TBL] [Abstract][Full Text] [Related]
11. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS.
Hughes PM; Botham MS; Frentzel S; Mir A; Perry VH
Glia; 2002 Mar; 37(4):314-27. PubMed ID: 11870871
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of fractalkine/CX3CL1 and fractalkine receptor (CX3CR1) expression in abdominal aortic aneurysm disease.
Patel A; Jagadesham VP; Porter KE; Scott DJ; Carding SR
Eur J Vasc Endovasc Surg; 2008 Jul; 36(1):20-7. PubMed ID: 18296082
[TBL] [Abstract][Full Text] [Related]
13. Fractalkine in vascular biology: from basic research to clinical disease.
Umehara H; Bloom ET; Okazaki T; Nagano Y; Yoshie O; Imai T
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):34-40. PubMed ID: 12969992
[TBL] [Abstract][Full Text] [Related]
14. The CX3CL1-CX3CR1 system and psoriasis.
Plant D; Young HS; Watson RE; Worthington J; Griffiths CE
Exp Dermatol; 2006 Nov; 15(11):900-3. PubMed ID: 17002687
[TBL] [Abstract][Full Text] [Related]
15. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human.
Foussat A; Coulomb-L'Hermine A; Gosling J; Krzysiek R; Durand-Gasselin I; Schall T; Balian A; Richard Y; Galanaud P; Emilie D
Eur J Immunol; 2000 Jan; 30(1):87-97. PubMed ID: 10602030
[TBL] [Abstract][Full Text] [Related]
16. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
[TBL] [Abstract][Full Text] [Related]
17. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients.
Ohta M; Tanaka F; Yamaguchi H; Sadanaga N; Inoue H; Mori M
Int J Oncol; 2005 Jan; 26(1):41-7. PubMed ID: 15586223
[TBL] [Abstract][Full Text] [Related]
18. Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1.
Nakayama T; Watanabe Y; Oiso N; Higuchi T; Shigeta A; Mizuguchi N; Katou F; Hashimoto K; Kawada A; Yoshie O
J Immunol; 2010 Dec; 185(11):6472-9. PubMed ID: 20974991
[TBL] [Abstract][Full Text] [Related]
19. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells.
Durkan AM; Alexander RT; Liu GY; Rui M; Femia G; Robinson LA
J Am Soc Nephrol; 2007 Jan; 18(1):74-83. PubMed ID: 17151328
[TBL] [Abstract][Full Text] [Related]
20. Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects.
Fodstad O; Hansen CT; Cannon GB; Statham CN; Lichtenstein GR; Boyd MR
Cancer Res; 1984 Oct; 44(10):4403-8. PubMed ID: 6467201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
